Cogent Biosciences Inc. (COGT)
Cogent Biosciences Inc. (COGT) Stock Price, Analysis & Data
| Bid | 27.77 |
| Market Cap | 6.76B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -377.18M |
| Beta | 0.33 |
| EPS (ttm) | -2.18 |
| PE Ratio (ttm) | n/a |
| Forward PE | -34.6 |
| P/B (ttm) | 14.31 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 3, 2026 |
| Ask | 48.7 |
| Volume | 2,977,657 |
| Avg. Volume (20D) | 2,520,477 |
| Open | 38.80 |
| Previous Close | 38.70 |
| Day's Range | 37.81 - 39.03 |
| 52-Week Range | 11.41 - 43.73 |
| Analyst | Strong Buy |
| Price Target | 55 (41.10%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About COGT
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found...
Financial Performance
In 2025, Cogent Biosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -328.94M, an increase of 28.56%.
Financial StatementsAnalyst Forecast
According to 12 analyst ratings, the average rating for COGT stock is "Strong Buy". The 12-month stock price forecast is 55, which is upside of 41.1% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
